Skip to main content
. 2022 Jun 29;5(6):e2219407. doi: 10.1001/jamanetworkopen.2022.19407

Figure 2. Cumulative Incidence of Hepatocellular Carcinoma in Patients Receiving Tenofovir vs Entecavir.

Figure 2.

HR indicates hazard ratio. Shaded areas indicate 95% CIs.